-
uniQure Announces First Quarter 2026 Financial Results and Provides Recent Company Updates
-
RBC Capital Upgrades uniQure BV (QURE) to Outperform
-
RBC Capital Downgrades uniQure BV (QURE) to Sector Perform, Lowers PT to $11
-
RBC Capita on uniQure BV (QURE): 'The Commissioner's comments are clearly disappointing'
-
uniQure BV (QURE) PT Lowered at RBC Capital After a 'Disappointing Regulatory Update'
-
uniQure BV (QURE) PT Raised to $20 at RBC Capital as 'FDA Leniency Materially De-risks HD'
-
uniQure Announces First Quarter 2024 Financial ResultsĀ and Highlights Recent Company Progress
-
RBC Capital on uniQure BV (QURE): 'Brain Safety Signal Unfortunate, But Stock Reaction Overdone'
-
uniQure Announces First Quarter 2021 Financial Results and Highlights Recent Company Progress
-
uniQure to Participate in Multiple Upcoming Industry Conferences in May
-
Ionis Pharmaceuticals (IONS) PT Lowered to $65 at RBC Capital After Tominersen Phase III Study was Discontinued
-
uniQure to Present at the RBC Capital Markets 2016 Global Healthcare Conference
-
Notable Analyst Rating Changes 12/1: (NOK) (TERP) (MRK) Upgraded; (ADRO) (REXX) (CMI) Downgraded
-
Pre-Open Stock Movers 04/23: (ARRS) (DNKN) (SKX) Higher; (MOBL) (MTH) (TXN) Lower (more...)
-
After-Hours Stock Movers 4/22: (AFOP) (EBAY) (CAKE) Higher; (TXN) (LVS) (FB) Lower (more..)
-
Notable Analyst Rating Changes 4/14: (PAY) (AEZS) (MDR) Upgraded; (AMTD) (SANM) (WWWW) Downgraded
-
Notable Analyst Rating Changes 03/03: (NOK) (KATE) (TDS) Upgraded; (ADSK) (AZN) (RIO) Downgraded


